Revolution Medicines has filed a patent for macrocyclic compounds that can inhibit Ras proteins, potentially leading to the treatment of cancers. The compounds have a specific structure and can be used in pharmaceutical compositions and protein complexes. The patent claim provides detailed information about the structure and substitutions of the compounds. GlobalData’s report on Revolution Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revolution Medicines, cancer treatment biomarkers was a key innovation area identified from patents. Revolution Medicines's grant share as of September 2023 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for macrocyclic compounds inhibiting ras proteins
A recently filed patent (Publication Number: US20230303591A1) describes a compound and its pharmaceutically acceptable salt, which can be used in the treatment of cancer. The compound has a specific chemical structure, as defined in Formula I, and can be further modified with various substitutions. The compound includes a heterocycloalkylene, cycloalkylene, arylene, or heteroarylene group, which can be optionally substituted. The compound also includes three independent groups, X1, X2, and X3, which can be selected from CH2, CHF, CF2, C-O, or O. The compound may have one or two m groups and zero or one n group. The R1 group can be hydrogen, optionally substituted heteroalkyl, or optionally substituted heterocycloalkyl. The R2 group can be optionally substituted alkyl, and the R3 group can be optionally substituted alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl. Each hydrogen in the compound can be isotopically enriched for deuterium.
The patent also describes specific variations of the compound. For example, in claim 2, R1 is specifically mentioned as hydrogen or optionally substituted heterocycloalkyl. Claim 5 specifies that m is 1 and n is 1. Claim 7 states that each of X1, X2, and X3 is CH2. Additionally, the patent includes various formulas (Formula II, Formula V, Formula VI, and Formula VII) that represent different structures of the compound.
The patent further discusses the use of the compound in pharmaceutical compositions for the treatment of cancer. Claim 27 specifically mentions a pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient. Claim 28 describes a method of treating cancer by administering a therapeutically effective amount of the compound to a subject in need.
In addition to the compound, the patent also covers a conjugate structure (Formula III) and its salt. The conjugate includes a monovalent organic moiety (P1) and a structure (Formula IV) that is similar to the compound described earlier.
Overall, this patent presents a compound and its variations, along with their potential use in the treatment of cancer. The compound's specific chemical structure and possible substitutions are defined, and its pharmaceutical compositions and methods of treatment are also disclosed.
To know more about GlobalData’s detailed insights on Revolution Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
